Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Akeso, Inc.
康方生物科技（開曼）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT
ON-MARKET SHARE PURCHASE

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Group.

Reference is made to the announcement of the Company dated June 11, 2026 (the "**Announcement**") in relation to the proposed on-market share purchase to be conducted by the trustee of the Company's 2021 restricted share unit scheme. Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

On November 16, 2026, the trustee purchased 336,000 Shares on the market for a total consideration of approximately HK$21 million. The Board believes that the share purchase reflects the Company's confidence in its business outlook and future prospects. The share purchase was funded by the Company's existing available cash resources.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive Director

Hong Kong, November 16, 2026

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.